On July 22, 2025, Denali Capital Acquisition Corp. amended its merger agreement with Semnur Pharmaceuticals to adjust share definitions for a business combination, maintaining a 1.25-to-1 exchange ratio. The registration statement for this merger is also pending with the SEC.